The impact of preoperative patient characteristics on the cost-effectiveness of total hip replacement: a cohort study

BMC Health Services Research

Werner Plötz³  Christian Lausmann²  Rainer Wilkesmann²  Matthias Vogl¹ 

[1] Ludwig-Maximilians-Universität München, Munich School of Management, Institute of Health Economics and Health Care Management & Munich Center of Health Sciences, Munich, Germany;Department of Orthopaedics and Trauma Surgery, Krankenhaus Barmherzige Brüder München, Akademisches Lehrkrankenhaus der Technischen Universität München, Romanstraße 93, Munich 80639, Germany;Klinikum rechts der Isar, Technical University Munich, Munich, Germany

关键词: Hip;    Total hip replacement;    WOMAC;    EQ-5D;    QALY;    Cost-utility;    Cost-effectiveness;    Costs;    Health-related quality of life;   

Others  :  1126767
DOI  :  10.1186/1472-6963-14-342

 received in 2014-02-03, accepted in 2014-08-07,  发布年份 2014

【 摘 要 】

Background

To facilitate the discussion on the increasing number of total hip replacements (THR) and their effectiveness, we apply a joint evaluation of hospital case costs and health outcomes at the patient level to enable comparative effectiveness research (CER) based on the preoperative health state.

Methods

In 2012, 292 patients from a German orthopedic hospital participated in health state evaluation before and 6 months after THR, where health-related quality of life (HRQoL) and disease specific pain and dysfunction were analyzed using EQ-5D and WOMAC scores. Costs were measured with a patient-based DRG costing scheme in a prospective observation of a cohort. Costs per quality-adjusted life year (QALY) were calculated based on the preoperative WOMAC score, as preoperative health states were found to be the best predictors of QALY gains in multivariate linear regressions.

Results

Mean inpatient costs of THR were 6,310 Euros for primary replacement and 7,730 Euros for inpatient lifetime costs including revisions. QALYs gained using the U.K. population preference-weighted index were 5.95. Lifetime costs per QALY were 1,300 Euros.

Conclusions

The WOMAC score and the EQ-5D score before operation were the most important predictors of QALY gains. The poorer the WOMAC score or the EQ-5D score before operation, the higher the patient benefit. Costs per QALY were far below common thresholds in all preoperative utility score groups and with all underlying calculation methodologies.

【 授权许可】

   
2014 Vogl et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Kurtz S, Ong K, Lau E, Mowat F, Halpern M: Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007, 89(4):780-785.
• [2]OECD: Health at a Glance Europe. 2012. http://www.oecd.org/els/health-systems/HealthAtAGlanceEurope2012.pdf webcite
• [3]Gesundheitsberichterstattung des Bundes: Die 50 häufigsten Operationen der vollstationären Patientinnen und Patienten in Krankenhäusern. http://www.gbe-bund.de/oowa921-install/servlet/oowa/aw92/dboowasys921.xwdevkit/xwd_init?gbe.isgbetol/xs_start_neu/&p_aid=i&p_aid=34158371&nummer=666&p_sprache=D&p_indsp=99999999&p_aid=25608545 webcite
• [4]Learmonth ID, Young C, Rorabeck C: The operation of the century: total hip replacement. Lancet 2007, 370(9597):1508-1519.
• [5]Jenkins PJ, Clement ND, Hamilton DF, Gaston P, Patton JT, Howie CR: Predicting the cost-effectiveness of total hip and knee replacement: a health economic analysis. Bone Joint J 2013, 95-B(1):115-121.
• [6]Dakin H, Gray A, Fitzpatrick R, Maclennan G, Murray D: Rationing of total knee replacement: a cost-effectiveness analysis on a large trial data set. BMJ Open 2012, 2(1):e000332.
• [7]Dall GF, Ohly NE, Ballantyne JA, Brenkel IJ: The influence of pre-operative factors on the length of in-patient stay following primary total hip replacement for osteoarthritis: a multivariate analysis of 2302 patients. J Bone Joint Surg (Br) 2009, 91(4):434-440.
• [8]Biring GS, Masri BA, Greidanus NV, Duncan CP, Garbuz DS: Predictors of quality of life outcomes after revision total hip replacement. J Bone Joint Surg (Br) 2007, 89(11):1446-1451.
• [9]Davis AM, Agnidis Z, Badley E, Kiss A, Waddell JP, Gross AE: Predictors of functional outcome two years following revision hip arthroplasty. J Bone Joint Surg Am 2006, 88(4):685-691.
• [10]Fortin PR, Clarke AE, Joseph L, Liang MH, Tanzer M, Ferland D, Phillips C, Partridge AJ, Belisle P, Fossel AH, Mahomed N, Sledge CB, Katz JN: Outcomes of total hip and knee replacement: preoperative functional status predicts outcomes at six months after surgery. Arthritis Rheum 1999, 42(8):1722-1728.
• [11]Hawker GA, Badley EM, Borkhoff CM, Croxford R, Davis AM, Dunn S, Gignac MA, Jaglal SB, Kreder HJ, Sale JE: Which patients are most likely to benefit from total joint arthroplasty? Arthritis Rheum 2013, 65(5):1243-1252.
• [12]Nilsdotter AK, Lohmander LS: Age and waiting time as predictors of outcome after total hip replacement for osteoarthritis. Rheumatology (Oxford) 2002, 41(11):1261-1267.
• [13]Nilsdotter AK, Petersson IF, Roos EM, Lohmander LS: Predictors of patient relevant outcome after total hip replacement for osteoarthritis: a prospective study. Ann Rheum Dis 2003, 62(10):923-930.
• [14]Roder C, Parvizi J, Eggli S, Berry DJ, Muller ME, Busato A: Demographic factors affecting long-term outcome of total hip arthroplasty. Clin Orthop Relat Res 2003, 417:62-73.
• [15]Roder C, Staub LP, Eggli S, Dietrich D, Busato A, Muller U: Influence of preoperative functional status on outcome after total hip arthroplasty. J Bone Joint Surg Am 2007, 89(1):11-17.
• [16]Santaguida PL, Hawker GA, Hudak PL, Glazier R, Mahomed NN, Kreder HJ, Coyte PC, Wright JG: Patient characteristics affecting the prognosis of total hip and knee joint arthroplasty: a systematic review. Can J Surg 2008, 51(6):428-436.
• [17]Young NL, Cheah D, Waddell JP, Wright JG: Patient characteristics that affect the outcome of total hip arthroplasty: a review. Can J Surg 1998, 41(3):188-195.
• [18]Bozic KJ, Katz P, Cisternas M, Ono L, Ries MD, Showstack J: Hospital resource utilization for primary and revision total hip arthroplasty. J Bone Joint Surg Am 2005, 87(3):570-576.
• [19]Antoniou J, Martineau PA, Filion KB, Haider S, Zukor DJ, Huk OL, Pilote L, Eisenberg MJ: In-hospital cost of total hip arthroplasty in Canada and the United States. J Bone Joint Surg Am 2004, 86-A(11):2435-2439.
• [20]Chang RW, Pellisier JM, Hazen GB: A cost-effectiveness analysis of total hip arthroplasty for osteoarthritis of the hip. JAMA 1996, 275(11):858-865.
• [21]Daigle ME, Weinstein AM, Katz JN, Losina E: The cost-effectiveness of total joint arthroplasty: a systematic review of published literature. Best Pract Res Clin Rheumatol 2012, 26(5):649-658.
• [22]Stargardt T: Health service costs in Europe: cost and reimbursement of primary hip replacement in nine countries. Health Econ 2008, 17(1 Suppl):S9-S20.
• [23]Rawlins MD, Culyer AJ: National Institute for Clinical Excellence and its value judgments. BMJ 2004, 329(7459):224-227.
• [24]Giacomini M: How good is good enough? Standards in policy decisions to cover new health technologies. Healthc Policy 2007, 3(2):91-101.
• [25]Altman DG: Systematic reviews of evaluations of prognostic variables. BMJ 2001, 323(7306):224-228.
• [26]Vogl M: Assessing DRG cost accounting with respect to resource allocation and tariff calculation: the case of Germany. Heal Econ Rev 2012, 2(1):15.
• [27]Leidl R, Reitmeir P: A value set for the EQ-5D based on experienced health states: development and testing for the German population. PharmacoEconomics 2011, 29(6):521-534.
• [28]Statistisches Bundesamt [Federal Statistical Office]: Periodensterbetafeln für Deutschland [Life Tables for Germany]. https://www.destatis.de/DE/Publikationen/Thematisch/Bevoelkerung/Bevoelkerungsbewegung/PeriodensterbetafelnBundeslaender.html webcite
• [29]Whitehead SJ, Ali S: Health outcomes in economic evaluation: the QALY and utilities. Br Med Bull 2010, 96:5-21.
• [30]Robinson AH, Palmer CR, Villar RN: Is revision as good as primary hip replacement? A comparison of quality of life. J Bone Joint Surg (Br) 1999, 81(1):42-45.
• [31]Patil S, Garbuz DS, Greidanus NV, Masri BA, Duncan CP: Quality of life outcomes in revision vs primary total hip arthroplasty: a prospective cohort study. J Arthroplast 2008, 23(4):550-553.
• [32]Engesaeter LB, Engesaeter IO, Fenstad AM, Havelin LI, Karrholm J, Garellick G, Pedersen AB, Overgaard S: Low revision rate after total hip arthroplasty in patients with pediatric hip diseases. Acta Orthop 2012, 83(5):436-441.
• [33]Pennington M, Grieve R, Sekhon JS, Gregg P, Black N, van der Meulen JH: Cemented, cementless, and hybrid prostheses for total hip replacement: cost effectiveness analysis. BMJ 2013, 346:f1026.
• [34]Hershey JC, Asch DA, Jepson C, Baron J, Ubel PA: Incremental and average cost-effectiveness ratios: will physicians make a distinction? Risk Anal 2003, 23(1):81-89.
• [35]Deutsche Gesellschaft für Unfallchirurgie: Leitlinien der Deutschen Gesellschaft für Unfallchirurgie - Endoprothese bei Koxarthrose. http://www.awmf.org/uploads/tx_szleitlinien/012-006l_S1_Endoprothese_bei_Koxarthrose_2008.pdf webcite
• [36]Dolan P: Modelling valuations for health states: the effect of duration. Health Policy 1996, 38(3):189-203.
• [37]Barton GR, Sach TH, Avery AJ, Doherty M, Jenkinson C, Muir KR: Comparing the performance of the EQ-5D and SF-6D when measuring the benefits of alleviating knee pain. Cost Eff Resour Alloc 2009, 7:12.
• [38]Ostendorf M, van Stel HF, Buskens E, Schrijvers AJ, Marting LN, Verbout AJ, Dhert WJ: Patient-reported outcome in total hip replacement. A comparison of five instruments of health status. J Bone Joint Surg (Br) 2004, 86(6):801-808.
• [39]Veenhof C, Bijlsma JW, van den Ende CH, van Dijk GM, Pisters MF, Dekker J: Psychometric evaluation of osteoarthritis questionnaires: a systematic review of the literature. Arthritis Rheum 2006, 55(3):480-492.
• [40]Stucki G, Meier D, Stucki S, Michel BA, Tyndall AG, Dick W, Theiler R: Evaluation of a German version of WOMAC (Western Ontario and McMaster Universities) Arthrosis Index. Z Rheumatol 1996, 55(1):40-49.
• [41]Roos EM, Klassbo M, Lohmander LS: WOMAC osteoarthritis index. Reliability, validity, and responsiveness in patients with arthroscopically assessed osteoarthritis. Western Ontario and MacMaster Universities. Scand J Rheumatol 1999, 28(4):210-215.
• [42]Vogl M: Improving patient-level costing in the English and the German ‘DRG’ system. Health Policy 2013, 109(3):290-300.
• [43]Bland JM, Altman DG: Regression towards the mean. BMJ 1994, 308(6942):1499.
• [44]Geissler A, Scheller-Kreinsen D, Quentin W: Do diagnosis-related groups appropriately explain variations in costs and length of stay of hip replacement? A comparative assessment of DRG systems across 10 European countries. Health Econ 2012, 21(Suppl 2):103-115.
• [45]Rissanen P, Aro S, Sintonen H, Asikainen K, Slatis P, Paavolainen P: Costs and cost-effectiveness in hip and knee replacements. A prospective study. Int J Technol Assess Health Care 1997, 13(4):575-588.
• [46]McCabe C, Claxton K, Culyer AJ: The NICE cost-effectiveness threshold: what it is and what that means. PharmacoEconomics 2008, 26(9):733-744.
• [47]Bang H, Zhao H: Average cost-effectiveness ratio with censored data. J Biopharm Stat 2012, 22(2):401-415.
• [48]Ethgen O, Bruyere O, Richy F, Dardennes C, Reginster JY: Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature. J Bone Joint Surg Am 2004, 86-A(5):963-974.
• [49]James M, St Leger S, Rowsell KV: Prioritising elective care: a cost utility analysis of orthopaedics in the north west of England. J Epidemiol Community Health 1996, 50(2):182-189.
• [50]Bozic KJ, Saleh KJ, Rosenberg AG, Rubash HE: Economic evaluation in total hip arthroplasty: analysis and review of the literature. J Arthroplast 2004, 19(2):180-189.
• [51]National Institute for Health and Care Excellence (NICE): Osteoarthritis The care and management of osteoarthritis in adults. http://www.nice.org.uk/nicemedia/pdf/cg59niceguideline.pdf webcite
• [52]Porter ME: What is value in health care? N Engl J Med 2010, 363(26):2477-2481.